Since late June, the A-share shock rebounded and hit the 3000-point mark. Medical equipment, biomedical and other industries with good growth prospects have become one of the directions for market capital mining. Shenwan Hongyuan Securities’ statistics on July 4 showed that Shenwan Pharmaceutical Bio-index rose 3.70% in the previous trading week, ranking 10th in all Shenwan-level industries.
Benefiting from the outstanding performance of medical biology, the return on the net value of medical funds has risen. According to the statistics of Haitong Securities as of July 5, the GF Medical Index grading fund rose 4.14% in the past month, while the Shanghai and Shenzhen 300 Index rose 0.57%.
The policy has become a catalyst for the rise of the pharmaceutical industry. The 9th China Bio-industry Conference was held recently. The General Office of the State Council issued a document to promote the development of health care big data applications and the reform of medical service prices. Luo Guoqing, manager of Guangfa Pharmaceutical Index Fund, believes that China’s current total expenditure on health care accounts for slightly more than 5% of GDP, which is still nearly double the gap with developed countries. The room for improvement is large, and the growth rate of medical and health expenditure will continue to exceed GDP growth rate. In the context of policy support and an aging population, the pharmaceutical industry has enormous growth potential.
From the perspective of industry investment, the CSI Medical Index tracked by the GF Index Rating Fund has good industry representation and profitability. According to Wind statistics, from January 1, 2008 to July 6, 2016, the income of the CSI Medical Index was as high as 198.96%, which was not only higher than the market wide base index, but also higher than the pharmaceutical index of the whole market, indicating the subdivided medical industry. (Medical Devices + Medical Services) The index has a higher growth rate.
The GF China Medical Index Indexing Fund contains three types of products with different risk-returns, namely the GF Securities CSI Healthcare Fund, the Steady Revenue Share (A-share) and the Positive Revenue (B-Share). Among them, the ratio of fund share of GF Medical A share and Guangfa Medical B share has remained unchanged at 1:1. The three products are suitable for investors with different risk preferences.
The GF Securities Index Fund performed well in the market rally, and the fund tracked the high growth index, the CSI Medical Index. According to the data, the constituent stocks of the CSI Medical Index cover outstanding listed companies in the medical industry in the Shanghai and Shenzhen Stock Exchanges. The first quarter report of the GF Securities Index Fund showed that it held the leading companies in the fine-molecule industry such as medical equipment, biomedical and other medical equipment such as Lepu Medical, Guanxi Biological, and Daan Gene.
Minsheng Securities issued a strategy report that policies such as the deepening of medical reform, the normalization of medical insurance control fees, and the reform of vaccine sales are gradually being promoted, and the unfavorable factors in the industry have been gradually released in the first half of the year. Debon Securities believes that this year's medical device industry is clearly receiving policy support. Regardless of the "13th Five-Year Plan" or the "Made in China" promotion plan, etc., the innovative research and development and quality upgrade of domestic medical devices have been raised to unprecedented heights. From the perspective of layout time, the medical industry investment window is opening.
Phosphate Series,Trisodium Phosphate,Tripotassium Phosphate In Food,Dimagesium Hydrogen Phosphate
LIANYUNGANGLONGTAIWEI FOOD INGREDIENTS CO.,LTD. , https://www.longtaiweifood.com